News | September 12, 2012

Positron, Jubilant DraxImage Collaborate on Supply of Strontium-82, Rubidium-82 Generators

New source of nuclear imaging tracers will offer alternative source for radiopharmaceuticals

September 12, 2012  – Positron Corp. announced that Jubilant DraxImage Inc., a Jubilant Life Sciences company, and Positron, have executed a Letter of Intent pertaining to:

  • Positron's supply of Active Pharmaceutical Ingredient (API) grade strontium (Sr)-82 for the JDI Sr-82/rubidium (Rb)-82 generator;
  • JDI's and Positron's co-promotion of JDI Sr-82/Rb-82 generators to end-users (upon FDA clearance); and
  • Positron's lifecycle management for expired JDI Sr-82/Rb-82 generators.

 

The strategic alliance between JDI and Positron will facilitate the stabilization, security and growth of the industry by increasing the supply of radioisotopes and radiopharmaceuticals. The parties expect that it will also provide considerable benefits to both parties: Positron secures a generator supply for future sales of cardiac positron emission tomography (PET) scanners and a customer for Sr-82; JDI secures a reliable supply of Sr-82, a vendor for expired generators management and a strategic partner with a growing customer base of cardiac PET scanners installed and serviced.

Martyn Coombs, president of JDI, stated, "Through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), Positron positioned itself as the only private entity in the United States with the practical experience of servicing the Sr-82/Rb-82 generator lifecycle. Their ability to provide a more stable and secure supply of API Sr-82 and management of expired Sr-82/Rb-82 generators fits well with JDI's pre-launch strategy."

Patrick Rooney, chief executive officer of Positron, stated, "JDI has developed a robust Sr-82/Rb-82 generator and elution system. As the Sr-82/Rb-82 generator on the market has enjoyed tremendous growth and the merits of the technology have been validated many times over, we strongly believe that the arrival of an alternative, upon the U.S. Food and Drug Administration (FDA) clearance of JDI's generator, will be welcomed by the cardiac PET community."

JDI and Positron expect to complete a Definitive Agreement within three months.

For more information: www.draximage.com and www.positron.com


Related Content

News | PET Imaging

October 5, 2023 — Jubilant DraxImage Inc., a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an ...

Home October 05, 2023
Home
News | PET Imaging

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Home December 01, 2022
Home
News | PET Imaging

September 14, 2022 — GE Healthcare and Lantheus Holdings Inc have announced that the recent Phase III clinical trial of ...

Home September 14, 2022
Home
News | PET Imaging

August 25, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron ...

Home August 25, 2022
Home
News | PET Imaging

June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...

Home June 15, 2022
Home
Technology | PET Imaging

December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ...

Home December 05, 2018
Home
News | PET Imaging

July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new ...

Home July 17, 2018
Home
News | PET Imaging

July 7, 2017 — Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are ...

Home July 07, 2017
Home
News | PET Imaging

March 3, 2017 — In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers ...

Home March 03, 2017
Home
News | PET Imaging

September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular ...

Home September 01, 2016
Home
Subscribe Now